Profiles of Immune Infiltration and Prognostic Immunoscore in Lung Adenocarcinoma

Table 1

Validation of the immunoscore results in the training and validation cohort in the TCGA database.

Variable	Training cohort		Validation cohort
	value	Hazard ratio (95% CI)	value	Hazard ratio(95% CI)
M	0.897		0.810
M0	0.698	0.753 (0.180-3.149)	0.541	0.642 (0.155-2.663)
M1	0.647	0.723 (0.180-2.898)	0.622	0.699 (0.168-2.901)
N	0.621		0.759
N0	0.505	0.617 (0.149-2.554)	0.766	0.710 (0.074-6.828)
N1-3	0.329	0.581 (0.196-1.727)	0.457	0.693 (0.264-1.822)
T	0.241		0.813
T1	0.152	0.285 (0.051-1.586)	0.314	7.388 (0.203-14.299)
T2	0.459	0.590 (0.146-2.385)	0.806	0.842 (0.214-3.317)
T3	0.606	0.842 (0.438-1.620)	0.990	0.922 (0.266-3.700)
T4	0.800	1.724 (0.279-5.236)	0.796	1.208 (0.288-5.067)
Stage	0.144		0.785
Stage1	0.133	0.408 (0.126-1.315)	0.326	0.520 (0.141-1.921)
Stage2	0.023	1.263 (1.016-1.832)	0.389	0.555 (0.145-2.119)
Stage3-4	0.418	0.802 (0.470-1.368)	0.711	0.877 (0.438-1.757)
Gender	0.648		0.782	0.682 (0.216-1.243)
Man	0.369	0.781 (0.455-1.340)	0.619	0.856 (0.463-1.582)
Woman	0.364	0.787 (0.469-10320)	0.546	1.207 (0.655-2.223)
Immune score	0.029	2.570(1.537-4.301)	0.001	1.419(1.152-1.844)
	0.062	1.016(0.969-1.021)	0.325	1.027(0.988-1.036)